1. Home
  2. INOD vs NRIX Comparison

INOD vs NRIX Comparison

Compare INOD & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INOD
  • NRIX
  • Stock Information
  • Founded
  • INOD 1988
  • NRIX 2009
  • Country
  • INOD United States
  • NRIX United States
  • Employees
  • INOD N/A
  • NRIX N/A
  • Industry
  • INOD EDP Services
  • NRIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • INOD Technology
  • NRIX Health Care
  • Exchange
  • INOD Nasdaq
  • NRIX Nasdaq
  • Market Cap
  • INOD 1.2B
  • NRIX 1.4B
  • IPO Year
  • INOD 1993
  • NRIX 2020
  • Fundamental
  • Price
  • INOD $61.91
  • NRIX $16.87
  • Analyst Decision
  • INOD Strong Buy
  • NRIX Strong Buy
  • Analyst Count
  • INOD 4
  • NRIX 16
  • Target Price
  • INOD $55.00
  • NRIX $31.75
  • AVG Volume (30 Days)
  • INOD 2.4M
  • NRIX 658.9K
  • Earning Date
  • INOD 02-20-2025
  • NRIX 04-09-2025
  • Dividend Yield
  • INOD N/A
  • NRIX N/A
  • EPS Growth
  • INOD N/A
  • NRIX N/A
  • EPS
  • INOD 0.89
  • NRIX N/A
  • Revenue
  • INOD $170,461,000.00
  • NRIX $54,549,000.00
  • Revenue This Year
  • INOD $93.11
  • NRIX $3.28
  • Revenue Next Year
  • INOD $34.30
  • NRIX $6.73
  • P/E Ratio
  • INOD $69.56
  • NRIX N/A
  • Revenue Growth
  • INOD 96.44
  • NRIX N/A
  • 52 Week Low
  • INOD $5.46
  • NRIX $10.17
  • 52 Week High
  • INOD $71.00
  • NRIX $29.56
  • Technical
  • Relative Strength Index (RSI)
  • INOD 72.96
  • NRIX 35.92
  • Support Level
  • INOD $48.50
  • NRIX $16.56
  • Resistance Level
  • INOD $62.32
  • NRIX $18.07
  • Average True Range (ATR)
  • INOD 4.45
  • NRIX 0.91
  • MACD
  • INOD 2.12
  • NRIX -0.13
  • Stochastic Oscillator
  • INOD 75.49
  • NRIX 9.95

About INOD Innodata Inc.

Innodata Inc is a digital services and solutions company. It provides technology and services to information products and online retail destinations. The company has three operating segments: Digital data solutions, Synodex, and Agility. It serves publishers, media and information companies, digital retailers, banks, insurance companies, government agencies, and other industries. Geographically, it operates in the United States, United Kingdom, Netherlands, Canada, and Europe.

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Share on Social Networks: